Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for lithium-induced nephrogenic diabetes insipidus
ACTRN12613000195752Phase 4Terminated
- Sponsor
- University of Otago
- Start
- May 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of acetazolamide in Arginine Vasopressin Resistance (AVP-R), sponsored by University of Otago. Primary endpoint: Change in urinary concentrating ability. Started May 2013; status: terminated.
02
Drugs
acetazolamide
03
Conditions
Arginine Vasopressin Resistance (AVP-R)
Beyond the preview
Go deeper on ACTRN12613000195752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000195752.